Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × tremelimumab × Clear all
NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Ludwig Institute for Cancer Research

Phase 1/2 Completed
73 enrolled 18 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡